KRAS and cancer: Some of the significant cancer hallmark terms are epithelial-mesenchymal transition (MSX1, CXCL12, SCG2, SLIT2), KRAS signaling up (F13A1, ADAMDEC1), inflammatory response (CCL5, VIP), IL-6/JAK/STAT3 signaling (CXCL13).